Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum LP28
- Development stage
- Preclinical
- Lead developer
- Synbio Tech
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum LP28 (formerly Lactobacillus plantarum LP28) is a probiotic bacterial strain originally isolated from traditional Taiwanese dried tofu (Daxi dried tofu). Developed by SynbioTech, it is marketed under the brand name Synmue. LP28 has been shown to support immune resilience and healthy aging by increasing natural killer (NK) cell cytotoxic activity, reducing inflammatory burden (such as C-reactive protein), and improving immune regulation (such as interleukin-12). It also enhances the production of short-chain fatty acids (SCFAs) and strengthens anti-inflammatory responses in the gut. LP28 is utilized as a dietary supplement and functional food ingredient for gut health, immune support, and healthy aging.
- Brand names
- Synmue
- Other names
- Lactobacillus plantarum LP28
02
Targets
IFNG (Interferon gamma)IL10 (Interleukin-10)IL12B (Interleukin-12/23 p40 subunit)IL-4 (Interleukin 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)TLR9 (Toll-like receptor 9)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Lactiplantibacillus plantarum LP28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum LP28.